Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics reports company developments as a commercial-stage biopharmaceutical company focused on immuno-dermatology and medical dermatology. Its recurring updates center on ZORYVE (roflumilast) cream and foam, a topical PDE4 inhibitor portfolio used across inflammatory skin diseases including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
Company news commonly covers ZORYVE net product revenue, demand trends for branded non-steroidal topical treatments, clinical data from dermatology studies, FDA submissions tied to potential label expansion, medical-meeting presentations, guideline references, sales-force and commercial updates, conference participation, and equity grants made under Nasdaq inducement-grant rules.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the grant of 50,250 restricted stock units and options to purchase 8,000 shares to seven new employees, as part of the 2022 Inducement Plan. These awards were approved by the Compensation Committee and are aimed at attracting talent in the company's early commercial-stage environment, effective February 1, 2023. The stock options have a ten-year term and an exercise price of $16.84 per share. The restricted stock units vest over four years, with a 25% annual vesting schedule. Arcutis is committed to addressing urgent needs in immuno-dermatology through its innovative therapies and clinical programs.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced promising long-term data from its Phase 2 study of roflumilast cream (0.3%), an FDA-approved treatment for chronic plaque psoriasis. The study, presented at the Winter Clinical dermatology meeting, showed that 57.1% of participants achieved an Investigator Global Assessment (IGA) score of clear or almost clear, with a median duration of 40.1 weeks. Efficacy remained consistent over 52 weeks, and the cream was well-tolerated with low discontinuation rates. Key findings included sustained IGA success across different patient cohorts and no signs of tachyphylaxis, reinforcing roflumilast cream's position as a preferred treatment for psoriasis.
On January 5, 2023, Arcutis Biotherapeutics (Nasdaq: ARQT) announced the granting of 17,050 restricted stock units and options for 33,550 shares to five new employees. These awards, approved by the Compensation Committee, are part of the 2022 Inducement Plan and are intended to incentivize new hires. The restricted stock units will vest over four years, while the stock options will also vest over the same period with specific vesting schedules. The options have a ten-year term with an exercise price of $14.77, reflecting the stock's closing price on the grant date.
Arcutis Biotherapeutics (Nasdaq: ARQT) has submitted a supplemental new drug application (sNDA) to the FDA for ZORYVE (roflumilast) cream 0.3%, seeking expanded approval for treating plaque psoriasis in children aged 2 to 11. The submission is supported by positive results from two 4-week studies demonstrating ZORYVE's safety and tolerability, with minimal local site reactions. If approved, ZORYVE will become the first steroid-free topical PDE4 inhibitor for this pediatric population, enhancing treatment options for children suffering from this common skin condition.
Arcutis Biotherapeutics (Nasdaq: ARQT) reported positive topline results from its INTEGUMENT-2 Phase 3 trial of roflumilast cream 0.15% for mild to moderate atopic dermatitis. The primary endpoint was met, with 28.9% achieving IGA Success versus 12.0% for vehicle (P0.0001). Significant improvements included 42.0% achieving EASI-75 and 30.2% with a reduction in itch at Week 4. The cream showed favorable safety and tolerability. Following these results, Arcutis plans to file a supplemental new drug application with the FDA in the second half of 2023.
Arcutis Biotherapeutics (Nasdaq: ARQT) announced the grant of 8,000 restricted stock units and options to purchase 18,000 shares of common stock to two new employees. This was approved by the Compensation Committee under the 2022 Inducement Plan, effective December 1, 2022. The stock options have a ten-year term with an exercise price of $17.08 per share. The restricted stock units vest over four years, while the stock options vest similarly over four years, contingent on continuous employment.
Arcutis Biotherapeutics (Nasdaq: ARQT) has announced the enrollment of the first subject in a Phase 1b study for ARQ-255, a new topical JAK1 inhibitor designed for alopecia areata treatment. This formulation utilizes proprietary 4D technology to deliver the drug deep into the skin, targeting the hair follicle's inflammation. Alopecia areata affects approximately 1 in 500 adults, causing sudden hair loss and emotional distress. The study will focus on the safety and tolerability of ARQ-255 in healthy volunteers and those with patchy alopecia areata.
On December 1, 2022, MyHealthTeam launched MySebDermTeam, a dedicated online community for individuals living with seborrheic dermatitis, supported by Arcutis Biotherapeutics. The initiative aims to enhance diagnosis and treatment awareness as 5% of the population is affected by this condition, which is often under-diagnosed. A recent survey revealed it takes an average of 3.6 years for patients to seek care. The platform will offer educational resources including expert interviews and a symptom tracking guide to improve patient outcomes.
Arcutis Biotherapeutics (Nasdaq: ARQT) published positive Phase 2b trial results for roflumilast cream 0.3% in treating chronic plaque psoriasis, focusing on patient-reported outcomes. The data revealed significant reductions in itch by Week 2 compared to a vehicle. Patients using roflumilast experienced notable improvements in itch-related sleep loss during Weeks 6 to 12. This cream is a selective phosphodiesterase-4 inhibitor, highlighting its rapid effectiveness. The study was published in the American Journal of Clinical Dermatology, reaffirming roflumilast's role in managing plaque psoriasis.
Arcutis Biotherapeutics (Nasdaq: ARQT) has successfully added its drug ZORYVE (roflumilast) cream 0.3% to Express Scripts’ national formularies, effective November 18, 2022. This non-steroidal cream is the first topical PDE4 inhibitor approved for plaque psoriasis, providing access to over 26 million commercially insured patients in the U.S. The company launched ZORYVE on August 10, 2022, with a focus on affordability through responsible pricing and patient assistance programs. CEO Frank Watanabe highlighted the company's commitment to increasing access through further payer engagement.